Oral lyophilised microbiota for the treatment of ulcerative colitis

Affiliations

¹ Department of Medicine, Indiana University, Indiana, USA. Electronic address: mofische@iu.edu.
² Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Comment

Monika Fischer et al. Lancet Gastroenterol Hepatol. 2022 Feb.

. 2022 Feb;7(2):108-109.

doi: 10.1016/S2468-1253(21)00433-7. Epub 2021 Dec 2.

¹ Department of Medicine, Indiana University, Indiana, USA. Electronic address: mofische@iu.edu.
² Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

No abstract available

Conflict of interest statement

MF has participated in data safety monitoring or advisory boards for Rebiotix/Ferring. AK declares no competing interests.

Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
Haifer C, Paramsothy S, Kaakoush NO, Saikal A, Ghaly S, Yang T, Luu LDW, Borody TJ, Leong RW. Haifer C, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):141-151. doi: 10.1016/S2468-1253(21)00400-3. Epub 2021 Dec 2. Lancet Gastroenterol Hepatol. 2022. PMID: 34863330 Clinical Trial.